JAK2 R683G

CI-VAR-00003877Explore in graph →CIViC 2829

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL11
IGH::CRLF2 Fusion AND JAK2 R683G	Sirolimus	Predictive	D	Supports Sensitivity Response	3	submitted	EID7641 Xenografts were established from Ph-like ALL patient derived cells harboring CRLF2 rearrangements and JAK2 mutations. A xenograft with a JAK2 R683G mutation and IGH-CRLF2 rearrangement showed signific… (full text at CIViC) PMID 22955920 · Maude et al., 2012 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.